Resource guide
Hospice Pharmacy Compliance and Regulatory Guidance
A surveyor asks to see your hospice's written policy for disposing of unused controlled substances in a patient's home. Can your team produce it in the room, or does someone need to go find it? Hospice pharmacy compliance lives in exactly that kind of moment: not abstract policy, but whether the documentation and process actually hold up when someone asks. This guide walks through what CMS actually requires, where controlled substances create the most risk, and how the regulatory landscape is shifting in 2026.
A note before you dig in: this page is for general education and does not replace legal or regulatory counsel. Always verify current requirements with CMS, your state pharmacy board, and your own compliance and legal teams before changing policy.
The regulatory landscape hospice pharmacy operates under
Quick answer: Hospice pharmacy compliance sits at the intersection of CMS Conditions of Participation, DEA controlled substance rules, and a growing wave of state-level e-prescribing mandates, all layered on top of a fast-growing, increasingly scrutinized benefit.
Hospice is now the dominant end-of-life care model in the United States: 1.91 million Medicare beneficiaries received hospice care in 2024, and for the first time, more than half of all Medicare decedents (53.1%) were enrolled in hospice at the time of death (Alliance for Care at Home, 2025 Facts and Figures). That scale has brought closer attention from CMS. Quality reporting penalties have grown sharper in recent years, and CMS has proposed new transparency measures for FY 2027 (QAPIPlus, Hospice Compliance 2025; CMS Newsroom). Compliance isn't a static checklist. It's a moving target that tightens as the program grows.
What CMS requires for drugs and biologicals
Quick answer: Under 42 CFR 418.106, hospices must employ or contract with a qualified pharmacist for inpatient settings, ensure all drug orders are properly documented, and give the interdisciplinary group (IDG) a defined role in assessing whether patients can safely self-administer medications.
The core federal requirement governing hospice medications is 42 CFR § 418.106, the Condition of Participation covering drugs, biologicals, medical supplies, and durable medical equipment. In summary, it requires:
- Pharmacy management. Hospices providing inpatient care must employ or contract with a qualified licensed pharmacist who evaluates a patient's response to medication therapy, identifies potential adverse drug reactions, and recommends corrective action.
- Drug ordering. Authorized prescribers include physicians, nurse practitioners, and physician assistants not employed by the hospice. Verbal or electronic orders must be received by a licensed nurse, pharmacist, or physician and documented immediately, consistent with state and federal law.
- Interdisciplinary group role. The IDG assesses whether a patient can safely self-administer medications at home as part of ongoing care plan review, and must approve any patient self-administration in inpatient settings.
- Storage and equipment. Controlled substances must be locked in secure areas with access limited to authorized personnel, and durable medical equipment must meet Medicare DMEPOS supplier quality standards.
(Source: eCFR, Title 42, Part 418, Subpart D, Section 418.106.)
Controlled substances: storage, disposal, and documentation
Quick answer: Hospices must maintain written policies for managing and disposing of controlled substances in a patient's home, communicate those policies to patients and families in understandable language at the time of initial ordering, and document that the conversation happened.
This is one of the areas surveyors scrutinize most closely, and for good reason: hospice patients often have controlled substances in the home, sometimes in significant quantities, at a time when family members are under enormous stress. Per 42 CFR 418.106, hospices must:
- Establish written policies for managing and disposing of controlled drugs in the home.
- Provide those written policies to patients and families at the time medications are first ordered.
- Discuss disposal procedures in language the patient and family can understand, and document that the discussion took place.
- In inpatient facilities, maintain disposal records and report any discrepancies to state authorities.
If your team can't immediately produce the written policy, the documentation that it was discussed with a specific family, and a clean disposal record for inpatient settings, that's the gap to close before a survey finds it first.
EPCS: the state-by-state mandate wave
Quick answer: A growing number of states now require electronic prescribing of controlled substances (EPCS), meaning certain controlled-substance prescriptions must be transmitted electronically, subject to applicable state requirements and exceptions, and hospices that aren't ready face compliance risk and delayed medications alike.
A growing number of states have enacted EPCS mandates, with more expected to follow. Depending on the state, non-compliant prescriptions may be rejected and prescribers or pharmacies may face penalties. Our post The Ultimate Solution to EPCS State Mandate Compliance covers what's driving the shift (reduced prescription fraud, better tracking of controlled substances, faster prescribing) and what hospices need in place to comply without adding friction to an already time-sensitive process.
The upside for hospices that get ahead of this: e-prescribing built specifically for hospice can turn a compliance requirement into an efficiency gain. BetterRX’s ePrescribe is built into the platform, with no separate tools, logins, or third-party platforms, and supports signing for both controlled and non-controlled medications. A text alerts prescribers when a controlled medication is ready to sign.
Staying ahead of CMS quality reporting penalties
Quick answer: Since the FY 2025 rule, hospices that don’t meet CMS quality reporting requirements face a steeper penalty: a 4-percentage-point reduction to their annual payment update, up from 2 percentage points.
Compliance and finance are more connected than they might first appear. The FY 2025 rule raised the hospice quality-reporting penalty from 2% to 4% of the annual payment update, and CMS has proposed additional transparency measures for FY 2027 (QAPIPlus, Hospice Compliance 2025; CMS Newsroom). For the financial side of this picture, including the FY 2026 aggregate cap and payment update, see our companion guide, Hospice Pharmacy Costs: A Finance Leader's Guide.
How technology reduces compliance risk
Quick answer: The right medication management platform builds compliance into everyday operations, capturing audit trails and formulary decisions within the workflow instead of relying on someone remembering to file the paperwork later.
Compliance risk tends to concentrate wherever a process depends on memory rather than a system. BetterRX's platform maintains an embedded, always-current medication history along with comprehensive audit logging for prescriptions, incidents, SureScripts transactions, medication reviews, and platform activity, built around a simple idea: stay ahead of CMS and state regulations with embedded safeguards rather than after-the-fact reconstruction. BetterRX Guardrails™ apply the same logic to formulary compliance specifically, flagging non-formulary medications during import and requiring documented justification for any approved exception, so the audit trail builds itself as decisions are made.
Explore more:
